Suffering from severe asthma generally implies experiencing extremely debilitating and risky events, like frequent severe exacerbations, emergency visits, and hospitalizations, all resulting in a sensible reduction of the quality of life. Also, in the past, patients were dependent on the use of oral glucocorticoids, which put them at increased risk for serious and often life-threatening adverse events. Recently, new biologics for severe asthma have become available, which have benefitted many but not all patients. Observational real world data can be key to answer questions about the natural history, burden and costs of this disease and its mechanisms, identification of different phenotypes and prediction of therapy response.
SHARP is a Clinical Research Collaboration (CRC) sponsored by the European Respiratory Society (ERS) and unrestricted grants from 5 pharmaceutical companies (Sanofi, TEVA, Novartis, GSK, Chiesi). It aims to facilitate access to severe asthma specialists for all severe asthma patients and understanding of the heterogeneity in mechanisms of severe asthma by researches and clinical personnel. Among other initiatives, it includes the establishment of a federated data analysis platform for individual national severe asthma registries across Europe to provide a comprehensive description of patient characteristics, phenotypes, treatment strategies, treatment responses to support patient care and enable international collaboration within a distributed research network. This aim entails an extensive work on every single data source, in order to bring every internal codification and non-standard expression of the available clinical information to the essential common denominator of standardized, interoperable data.
This is where Biomeris is involved, in the management of the process of data harmonization of each national data source to the OMOP CDM. This entails close cooperation with clinical and domain experts, to bring forth the mapping and the subsequent translation of data in the desired format.